Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.
Hsu PI.
J Gastroenterol Hepatol. 2012 Apr;27(4):654-61. doi: 10.1111/j.1440-1746.2012.07085.x.
Related citations
Seeking an optimal eradication therapy for Helicobacter pylori infection.
Miura S, Hokari R.
J Gastroenterol Hepatol. 2012 Jan;27(1):7-9. doi: 10.1111/j.1440-1746.2011.06953.x. No abstract available.
Abstracts of the Asian Pacific Monothematic Meeting on Helicobacter Pylori 2012. January 13-15, 2012. Kuala Lumpur, Malaysia.
[No authors listed]
J Gastroenterol Hepatol. 2012 Jan;27 Suppl 1:1-36. No abstract available.
Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
Hongo M, Miwa H, Kusano M; J-FAST group.
J Gastroenterol Hepatol. 2012 May;27(5):913-8. doi: 10.1111/j.1440-1746.2011.07042.x.
Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.
Shimatani T, Sugimoto M, Nishino M, Adachi K, Furuta K, Ito M, Kurosawa S, Manabe N, Mannen K, Hongo M, Chiba T, Kinoshita Y; Acid-Related Symptom Research (ARS) Group.
J Gastroenterol Hepatol. 2012 May;27(5):899-906. doi: 10.1111/j.1440-1746.2011.06975.x.
High-dose esomeprazole is required for intraesophageal acid control in gastroesophageal reflux disease patients with hiatus hernia.
Peng S, Xiao YL, Cui Y, Lin JK, Zhang N, Hu PJ, Chen MH.
J Gastroenterol Hepatol. 2012 May;27(5):893-8. doi: 10.1111/j.1440-1746.2011.06969.x.
Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy.
Deguchi R, Nakaminami H, Rimbara E, Noguchi N, Sasatsu M, Suzuki T, Matsushima M, Koike J, Igarashi M, Ozawa H, Fukuda R, Takagi A.
J Gastroenterol Hepatol. 2012 May;27(5):888-92. doi: 10.1111/j.1440-1746.2011.06985.x.
Future candidates for indications of Helicobacter pylori eradication: do the indications need to be revised?
Lee SY.
J Gastroenterol Hepatol. 2012 Feb;27(2):200-11. doi: 10.1111/j.1440-1746.2011.06961.x. Review.
Oral manifestations of gastroesophageal reflux disease.
Ranjitkar S, Smales RJ, Kaidonis JA.
J Gastroenterol Hepatol. 2012 Jan;27(1):21-7. doi: 10.1111/j.1440-1746.2011.06945.x. Review.
Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.
Oh HS, Lee DH, Seo JY, Cho YR, Kim N, Jeoung SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Cho HJ, Jung HC, Song IS.
J Gastroenterol Hepatol. 2012 Mar;27(3):504-9. doi: 10.1111/j.1440-1746.2011.06922.x.
Prevalence of gastroesophageal reflux disease in Korea and associated health-care utilization: a national population-based study.
Kim KM, Cho YK, Bae SJ, Kim DS, Shim KN, Kim JH, Jung SW, Kim N.
J Gastroenterol Hepatol. 2012 Apr;27(4):741-5. doi: 10.1111/j.1440-1746.2011.06921.x.
Male sex, hiatus hernia, and Helicobacter pylori infection associated with asymptomatic erosive esophagitis.
Wang PC, Hsu CS, Tseng TC, Hsieh TC, Chen CH, Su WC, Lin HH, Wang CC.
J Gastroenterol Hepatol. 2012 Mar;27(3):586-91. doi: 10.1111/j.1440-1746.2011.06881.x.
Continuous proton pump inhibitor treatment decreases upper gastrointestinal bleeding and related death in rural area in Japan.
Miyamoto M, Haruma K, Okamoto T, Higashi Y, Hidaka T, Manabe N.
J Gastroenterol Hepatol. 2012 Feb;27(2):372-7. doi: 10.1111/j.1440-1746.2011.06878.x.
Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study.
Attumi TA, Graham DY.
J Gastroenterol Hepatol. 2012 Jan;27(1):59-61. doi: 10.1111/j.1440-1746.2011.06876.x.
Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance.
Chung JW, Lee GH, Jeong JY, Lee SM, Jung JH, Choi KD, Song HJ, Jung HY, Kim JH.
J Gastroenterol Hepatol. 2012 Mar;27(3):493-7. doi: 10.1111/j.1440-1746.2011.06874.x.
Use of acid suppressive therapy more than 10 years after the endoscopic diagnosis of reflux esophagitis with specific emphasis to trademark and generic proton pump inhibitors.
Dackus GH, Loffeld SM, Loffeld RJ.
J Gastroenterol Hepatol. 2012 Feb;27(2):368-71. doi: 10.1111/j.1440-1746.2011.06855.x.
CYP2C19 genotypes determine the efficacy of on-demand therapy of pantoprazole for reflux esophagitis as Los-Angeles grades C and D.
Sheu BS, Cheng HC, Yeh YC, Chang WL.
J Gastroenterol Hepatol. 2012 Jan;27(1):104-9. doi: 10.1111/j.1440-1746.2011.06848.x.
Helicobacter pylori outer membrane proteins on gastric mucosal interleukin 6 and 11 expression in Mongolian gerbils.
Sugimoto M, Ohno T, Graham DY, Yamaoka Y.
J Gastroenterol Hepatol. 2011 Nov;26(11):1677-84. doi: 10.1111/j.1440-1746.2011.06817.x.
Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan.
Yamade M, Sugimoto M, Uotani T, Nishino M, Kodaira C, Furuta T.
J Gastroenterol Hepatol. 2011 Sep;26(9):1457-61. doi: 10.1111/j.1440-1746.2011.06815.x.
Silent gastroesophageal disease: clinical implications of an unknown disease.
Goh KL, Ho SH.
J Gastroenterol Hepatol. 2011 Jun;26(6):941-2. doi: 10.1111/j.1440-1746.2011.06738.x. No abstract available.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on